Yuxing Cheng currently serves as the Director of Biologics Discovery at Johnson & Johnson, where he leverages his extensive expertise in antibody discovery and molecular biology to drive innovative therapeutic solutions. With a robust background in the pharmaceuticals industry, Yuxing has honed his skills in...
Yuxing Cheng currently serves as the Director of Biologics Discovery at Johnson & Johnson, where he leverages his extensive expertise in antibody discovery and molecular biology to drive innovative therapeutic solutions. With a robust background in the pharmaceuticals industry, Yuxing has honed his skills in various platforms for antibody discovery, including hybridoma technology, phage display, and single B cell approaches. His leadership in key projects focuses on developing novel biologics targeting infectious diseases, an area of critical importance in today’s healthcare landscape.
Under Yuxing’s direction, his team employs cutting-edge techniques such as flow cytometry, fluorescence microscopy, and high-throughput screening to facilitate the identification and characterization of potent antibodies. His proficiency in single B cell cloning and purification allows for the isolation of high-affinity antibodies, which are essential for advancing therapeutic candidates through the development pipeline. Yuxing’s commitment to scientific excellence is evident in his collaborative efforts to optimize B cell stimulation in vitro, enhancing the efficiency of antibody generation.
With a Doctor of Philosophy (PhD) in Biological Sciences, Yuxing Cheng combines his academic rigor with practical industry experience, making significant contributions to the field of biologics. His work not only aims to address pressing health challenges but also fosters a culture of innovation and scientific inquiry within his team at Johnson & Johnson. As he continues to lead transformative projects, Yuxing remains dedicated to pushing the boundaries of antibody discovery and advancing the next generation of biologic therapies.
